Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yisui Granule in Low and Medium Risk MDS
NCT05687513Phase 1Unknown
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Jan 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of Yisui Granule in myelodysplastic syndrome (MDS) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Methylation index at 8 weeks. Status: unknown.
02
Drugs
Yisui Granule
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05687513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687513.